Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 3NET 2Genitourinary 1

Conditions

Carcinoma, Renal Cell 71Prostatic Neoplasms 22Kidney Neoplasms 14Carcinoma, Transitional Cell 9Urinary Bladder Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Neoplasm Metastasis 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Hepatocellular 6Urethral Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Breast Neoplasms 3Brain Neoplasms 3Wilms Tumor 2Urologic Neoplasms 2Urogenital Neoplasms 2Ureteral Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Recurrence 2Penile Neoplasms 2Pancreatic Neoplasms 2Pain 2Osteosarcoma 2Melanoma 2

Interventions

cabozantinib 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1Biological Therapy 1Biological Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × cabozantinib × Genitourinary × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡